Cytek Biosciences, Inc.
NASDAQCytek Biosciences enters the week after Q1 results fighting a 15% price drop, fresh target cuts from two analysts, and a short base that remains stubbornly elevated. The stock closed at $4.04 on Tuesday, down from $4.78 a week earlier. The selloff follows last Wednesday's Q1 earnings report, which prompted a 6.7% one-day decline. Despite beating revenue estimates and reaffirming…
Snapshot as of 14 May 2026
Cytek Biosciences enters the week after Q1 results fighting a 15% price drop, fresh target cuts from two analysts, and a short base that remains stubbornly elevated. The stock closed at $4.04 on Tuesday, down from…
Cytek Biosciences enters its post-earnings stretch on the back foot. Q1 EPS came in at -$0.15, missing the -$0.10 consensus by 50%, while revenue of $44.1M also fell short of estimates — and the stock gapped down 6.7%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CTKB — free to start on ORTEX.
Sign up for free →Open CTKB on ORTEX